-
Indivior Inc. et al v. Mylan Technologies Inc. et al DC CAFC
- 1:15-cv-01016
- D. Del.
- Judge: Richard G. Andrews
- Filed: 11/04/2015
- Closed: 09/05/2019
- Latest Docket Entry: 09/28/2020
- PACER
- Docket updated daily
3
Plaintiffs
4
Defendants
2
Accused
Products
4
Patents-in-Suit
1,402
Days in
Litigation
-
Indivior Inc. et al v. Mylan Technologies Inc. et al DC CAFC
- 1:15-cv-01016
- D. Del.
- Judge: Richard G. Andrews
- Filed: 11/04/2015
- Closed: 09/05/2019
- Latest Docket Entry: 09/28/2020
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A mucosally-adhesive water-soluble film product comprising: an analgesic opiate pharmaceutical active; and at least one water-soluble polymer component consisting of polyethylene oxide in combination with a hydrophilic cellulosic polymer; wherein:
view more
|
Valid
Entry 293 |
4 |
The film product according to claim 1, further comprising an additional pharmaceutical active.
|
Valid
Entry 293 |
5 |
The film product according to claim 1, further comprising one or more sweeteners.
|
Valid
Entry 293 |
8 |
The film product according to claim 1, further comprising one or more flavors.
|
Valid
Entry 293 |
9 |
The film product according to claim 1, further comprising one or more buffers.
|
Valid
Entry 293 |
Claim # | Claim Text | Outcome |
---|---|---|
62 |
A drug delivery composition comprising: (i) a cast film comprising a flowable water-soluble or water swellable film-forming matrix comprising one or more substantially water soluble or water swellable polymers; and a desired amount of at least one
view more
|
Valid
Entry 293 |
63 |
The drug delivery composition of claim 62, wherein the particulate active has a particle size of 150 microns or less.
|
Valid
Entry 293 |
65 |
The drug delivery composition of claim 62, wherein said variation of drug content is less than 5% by weight per film dosage unit.
|
Valid
Entry 293 |
69 |
The drug delivery composition of claim 62, wherein said taste-masking agent is present in the amount of about 0.1-30% by weight of the drug delivery composition.
|
Valid
Entry 293 |
71 |
The drug delivery composition of claim 62, wherein said active is selected from the group consisting of antimicrobial agents, non-steroidal anti-inflammatory drugs, anti-tussives, decongestants, antihistamines, expectorants, anti-diarrheals, H<sub>2
view more
|
Valid
Entry 293 |
73 |
The drug delivery composition of claim 62, wherein said active is an opiate or opiate derivative.
|
Valid
Entry 293 |
Claim # | Claim Text | Outcome |
---|---|---|
24 |
The process of claim 1, wherein said active is in the form of a particle.
|
Valid
Entry 293 |
-
Infringement
Mylan N.V.
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
generic version of the 2 mg/0.5 mg, 4 mg/I mg, 8 mg/2 mg, and 12 mg/3 mg dosage strengths of Plaintiffs' Suboxone® sublingual film | US 8,017,150 B2 |
1, 4, 5, 8, 9
|
No infringement
Entry 293
|
generic version of the 2 mg/0.5 mg, 4 mg/I mg, 8 mg/2 mg, and 12 mg/3 mg dosage strengths of Plaintiffs' Suboxone® sublingual film | US 8,603,514 B2 |
62, 63, 65, 69, 71, 73
|
No infringement
Entry 293
|
generic version of the 2 mg/0.5 mg, 4 mg/I mg, 8 mg/2 mg, and 12 mg/3 mg dosage strengths of Plaintiffs' Suboxone® sublingual film | US 8,900,497 B2 |
24
|
No infringement
Entry 293
|
Mylan Pharmaceuticals Incorporated
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
generic version of the 2 mg/0.5 mg, 4 mg/I mg, 8 mg/2 mg, and 12 mg/3 mg dosage strengths of Plaintiffs' Suboxone® sublingual film | US 8,017,150 B2 |
1, 4, 5, 8, 9
|
No infringement
Entry 293
|
generic version of the 2 mg/0.5 mg, 4 mg/I mg, 8 mg/2 mg, and 12 mg/3 mg dosage strengths of Plaintiffs' Suboxone® sublingual film | US 8,603,514 B2 |
62, 63, 65, 69, 71, 73
|
No infringement
Entry 293
|
generic version of the 2 mg/0.5 mg, 4 mg/I mg, 8 mg/2 mg, and 12 mg/3 mg dosage strengths of Plaintiffs' Suboxone® sublingual film | US 8,900,497 B2 |
24
|
No infringement
Entry 293
|
Mylan Technologies Incorporated
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
generic version of the 2 mg/0.5 mg, 4 mg/I mg, 8 mg/2 mg, and 12 mg/3 mg dosage strengths of Plaintiffs' Suboxone® sublingual film | US 8,017,150 B2 |
1, 4, 5, 8, 9
|
No infringement
Entry 293
|
generic version of the 2 mg/0.5 mg, 4 mg/I mg, 8 mg/2 mg, and 12 mg/3 mg dosage strengths of Plaintiffs' Suboxone® sublingual film | US 8,603,514 B2 |
62, 63, 65, 69, 71, 73
|
No infringement
Entry 293
|
generic version of the 2 mg/0.5 mg, 4 mg/I mg, 8 mg/2 mg, and 12 mg/3 mg dosage strengths of Plaintiffs' Suboxone® sublingual film | US 8,900,497 B2 |
24
|
No infringement
Entry 293
|